Analysis of more than 57,000 UK Biobank participants found that greater variation in blood pressure measurements between research visits was associated with increased risk of death, with some blood pressure measures also linked to stroke risk. The findings were presented at the European Association for the Study of Diabetes annual meeting.
A clinical trial led by Queen Mary University of London has found that transcutaneous autonomic neuromodulation through the ear is safe, well-tolerated, and easy for patients with uncontrolled hypertension to use at home. The SCRATCH-HTN trial demonstrates the potential of this noninvasive technique as a treatment option for high blood pressure.
A nationwide Danish study found that oral menopausal hormone therapy is associated with elevated risk of venous thromboembolism regardless of dose, while high-dose oral forms also increased stroke and heart attack risk. Transdermal treatments showed no overall increase in thrombotic risk.
A 46-year-old father standing 6ft 8in tall lost 32 stone after doctors warned him during open-heart surgery that his weight was endangering his life. He now believes he has the best chance of staying with his family.
Researchers have identified eight widely used food preservatives in processed foods that are associated with significantly higher rates of hypertension and cardiovascular disease, according to a large observational study conducted in France.
Multiple studies released this week show hormone therapy during menopause may reduce heart disease risk and improve mood symptoms, while supplements marketed for menopause lack evidence and contain inconsistent doses. The research comes amid growing attention to the economic costs of menopause symptoms for women.
The randomized SINGLE-AF trial, presented at ESC Congress 2026 and published in the New England Journal of Medicine, found that direct oral anticoagulants reduced serious clinical events by 69% in atrial fibrillation patients with intermediate stroke risk. The benefit was primarily driven by fewer ischemic strokes, with no increase in major bleeding.
Scientists have made a breakthrough in understanding the biology that triggers preeclampsia, a dangerous pregnancy complication that doubles women's risk of premature cardiovascular death and is a leading cause of maternal mortality and preterm birth.
New research published in The BMJ shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist, reduces the risk of major cardiovascular events by 33% in type 2 diabetes patients with existing heart disease. A separate study also found that consistent medication adherence among diabetes patients reduces heart disease risk by 27%.
New research indicates that Mounjaro (tirzepatide) significantly lowers the risk of heart attacks in type 2 diabetes patients who also have heart disease, with a 33% reduction observed in those receiving the medication.
New research published in The BMJ shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist, reduces the risk of major cardiovascular events by 33% in type 2 diabetes patients with existing heart disease. A separate study also found that consistent medication adherence among diabetes patients reduces heart disease risk by 27%.
A new study shows that tirzepatide (Mounjaro), a GLP-1 receptor agonist drug, reduces heart attack risk by 33% when added to standard care for patients with both type 2 diabetes and existing heart disease. The findings come as worldwide sales of the drug doubled to £13.8 billion in the first half of 2026.
UCLA researchers led by Melody Li have discovered that the SARS-CoV-2 nucleocapsid protein can suppress early antiviral responses while triggering inflammation that damages blood vessels, potentially explaining long COVID symptoms. The finding comes as separate research explores viral reactivation and psychosocial factors in long COVID patients.
The University of Oxford spinout Caristo has received FDA authorization for an AI-powered tool designed to assess heart attack risk in patients without obstructive coronary artery disease. The company plans to launch the cardiovascular risk predictor soon.
Study finds that kidney transplant recipients treated with remdesivir within a week of COVID-19 diagnosis and receiving at least three consecutive days of therapy experienced fewer cardiovascular complications compared to those who did not receive the antiviral treatment.
A novel pacemaker design the size of a sticker employs ultrasound technology rather than conventional wires to treat cardiac arrhythmia, offering a potential alternative to standard surgical pacemaker implantation for millions of patients worldwide.
Researchers at the University of Cape Town have issued a warning about potential health risks associated with pre-workout supplements following a case where an adult patient presented to the emergency unit with chest pain.
The U.S. Food and Drug Administration's Phase I voluntary sodium reduction targets, issued in 2021 to encourage manufacturers to lower sodium in packaged foods by 2024, appear to have had minimal effect on reducing sodium levels in food products.
A new study published in JAMA Cardiology reveals that approximately 90% of ischemic heart disease deaths in the United States remain attributable to modifiable risk factors including blood pressure, diet, and LDL cholesterol, despite significant declines in mortality since 1990. Research also shows these factors are linked to unstable coronary artery plaques that lead to heart attacks.
